Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MELK | Q14680 | 9/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | IKBKB | O14920 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3816421 | 0.90 | MELK (0.41) | KMT2APOLBMELKSMN1; SMN2CYP1A2 | |
| SCHEMBL4475686 | 0.88 | ALDH1A1 (0.45) | MEN1KMT2AMAPK1RAB9AMELK | |
| SCHEMBL4473963 | 0.88 | CYP1A2 (0.46) | MEN1KMT2APOLBRAB9AMELK | |
| SCHEMBL3824051 | 0.88 | USP30 (0.44) | KMT2APOLBMAPK1MELKSMN1; SMN2 | |
| SCHEMBL4467624 | 0.87 | USP30 (0.43) | POLBMAPK1RAB9AMELKSMN1; SMN2 | |
| SCHEMBL13711809 | 0.87 | MELK (0.39) | MEN1KMT2APOLBMELKSMN1; SMN2 | |
| SCHEMBL4476832 | 0.85 | USP30 (0.46) | MEN1KMT2APOLBMAPK1RAB9A | |
| SCHEMBL4469724 | 0.85 | KMT2A (0.41) | MEN1KMT2APOLBRAB9AMELK | |
| SCHEMBL13708142 | 0.84 | IKBKB (0.35) | MEN1KMT2APOLBMAPK1RAB9A | |
| SCHEMBL3819258 | 0.83 | ALDH1A1 (0.54) | MEN1KMT2APOLBMAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470821-B2 | PDE4B inhibitors and uses therefor | PLEXXIKON INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8470821-B2 | PDE4B inhibitors and uses therefor | PLEXXIKON INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8470821-B2 | PDE4B inhibitors and uses therefor | PLEXXIKON INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20090286793-A1 | PDE4B INHIBITORS AND USES THEREFOR | PLEXXIKON, INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090286793-A1 | PDE4B INHIBITORS AND USES THEREFOR | PLEXXIKON, INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090286793-A1 | PDE4B INHIBITORS AND USES THEREFOR | PLEXXIKON, INC. | 2009-11-19 | — | — | US | disclosed |
| US-7585859-B2 | PDE4B inhibitors and uses therefor | PLEXXIKON, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-7585859-B2 | PDE4B inhibitors and uses therefor | PLEXXIKON, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-7585859-B2 | PDE4B inhibitors and uses therefor | PLEXXIKON, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| EP-1742627-A4 | PDE4B INHIBITORS AND USES THEREFOR | PLEXXIKON INC (US) | 2009-08-26 | — | — | EP | disclosed |
| EP-1742627-A2 | PDE4B INHIBITORS AND USES THEREFOR | PLEXXIKON, INC. (US) | 2007-01-17 | — | — | EP | disclosed |
| WO-2006078287-A9 | PDE4B INHIBITORS AND USES THEREFOR | PLEXXIKON INC (US) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006078287-A2 | PDE4B INHIBITORS AND USES THEREFOR | PLEXXIKON, INC. (US) | 2006-07-27 | — | — | WO | disclosed |
| US-20060041006-A1 | PDE4B inhibitors and uses therefor | PLEXXIKON, INC. | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286793-A1 | PDE4B INHIBITORS AND USES THEREFOR | PDE4B, PDE7B, PDE4A | MEN1 2737/4885KMT2A 2234/4885POLB 248/4885 |
| US-20060041006-A1 | PDE4B inhibitors and uses therefor | PDE4B, PDE7B, PDE4A | MEN1 2737/4885KMT2A 2234/4885POLB 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.